Search Within

Eytan Moshe Stein

Formats
  1. Meeting Abstract (217)
  2. Journal Article (104)
  3. Review (17)
  4. Research Letter (14)
  5. Editorial (5)
  6. Book Section (3)
  7. Guidelines (2)
  8. Correspondence (1)
  9. Miscellaneous (1)
Groups
  1. Adult Leukemia (364)
  2. Center for Hematologic Malignancies (364)
  3. Department of Medicine (364)
  4. Hematologic Malignancies, Division of (364)
  5. GSK Faculty (92)
  6. Executive Committee, Center for Hematologic Malignancies (87)

More Groups

People
  1. Martin Tallman (116)
  2. Ross Levine (75)
  3. Aaron Goldberg (41)
  4. Jan Bewersdorf (33)
  5. Andriy Derkach (31)
  6. Christopher Famulare (30)

More People

Years
  1. 2025 (14)
  2. 2024 (44)
  3. 2023 (49)
  4. 2022 (34)
  5. 2021 (31)
  6. 2020 (30)

More Years

Publications
  1. Blood (170)
  2. Journal of Clinical Oncology (23)
  3. Clinical Lymphoma, Myeloma and Leukemia (17)
  4. Haematologica (16)
  5. Blood Advances (14)
  6. Leukemia and Lymphoma (12)

More Publications

Publishers
  1. American Society of Hematology (185)
  2. Elsevier Inc. (30)
  3. American Society of Clinical Oncology (27)
  4. Ferrata Storti Foundation (16)
  5. Nature Publishing Group (15)
  6. Taylor & Francis Group (12)

More Publishers

Results (364)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Initial report of the beat AML umbrella study for previously untreated AML: Evidence of feasibility and early success in molecularly driven phase 1 and 2 studies
    Meeting Abstract

    Burd, A.; Levine, R. L.; Shoben, A.; Mims, A. S.; Borate, U.; Stein, E. M.; Patel, P. A.; Baer, M. R.; Stock, W.; Deininger, M. W.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • AML with mutations in IDH1 and DNMT3A exhibits a distinct epigenetic signature with poorer overall survival
    Meeting Abstract

    Ahr, K.; Famulare, C.; Koche, R.; Spitzer, B.; Levine, R. L.; Tallman, M. S.; Goldberg, A. D.; Stein, E. M.; Glass, J. L.
    Blood (2018)

    Fulltext@MSK | Save
  • Emerging real-world midostaurin treatment patterns and outcomes in FLT3-mutated acute myeloid leukemia at a comprehensive cancer center
    Meeting Abstract

    Willis, C.; Menon, J.; Unni, S.; Au, T.; Ndife, B.; Joseph, G. J.; Bonifacio, G. J.; Stein, E. M.; Tantravahi, S. K.; Shami, P. J.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Phase 1b dose escalation study of BI 836858 and azacitidine in previously untreated AML: Results from Beat AML S2
    Meeting Abstract

    Blum, W.; Ruppert, A. S.; Mims, A. S.; Stein, E. M.; Duong, V. H.; Odenike, O.; Patel, P. A.; Kovacsovics, T.; Heerema, N. A.; Vergilio, J. A.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • AGILE: A phase 3, multicenter, randomized, placebo-controlled study of ivosidenib in combination with azacitidine in adult patients with previously untreated acute myeloid leukemia with an IDH1 mutation
    Meeting Abstract

    Stein, E.; Dinardo, C. D.; Jang, J. H.; Miyazaki, Y.; Martinez, R. O.; Auer, J.; Zhang, V.; Koralek, D. O.; Wu, B.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Inhibidores de la isocitrato deshidrogenasa mutata (mIDH), ivosidenib o enasidenib, en combinación con azacitidina (AZA) en pacientes con leucemia mieloide aguda (LMA)
    Meeting Abstract

    Montesinos, P.; Di Nardo, C. D.; Stein, A. S.; Stein, E. M.; Fathi, A. T.; Schuh, A. C.; Odenike, O.; Kantarjian, H. M.; Stone, R. M.; Collins, R.; more...
    Haematologica (2018)

    Fulltext@MSK | Save
  • Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition
    Journal Article

    Harding, J. J.; Lowery, M. A.; Shih, A. H.; Schvartzman, J. M.; Hou, S.; Famulare, C.; Patel, M.; Roshal, M.; Do, R. K.; Zehir, A.; more...
    Cancer Discovery (2018)

    Fulltext@MSK | Save
  • SOHO State of the Art Update and Next Questions: IDH therapeutic targeting in AML
    Journal Article

    DiNardo, C. D.; Stein, E. M.
    Clinical Lymphoma, Myeloma and Leukemia (2018)

    Fulltext@MSK | Save
  • Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States
    Journal Article

    Stein, E. M.; Yang, M.; Guerin, A.; Gao, W.; Galebach, P.; Xiang, C. Q.; Bhattacharyya, S.; Bonifacio, G.; Joseph, G. J.
    Health and Quality of Life Outcomes (2018)

    Fulltext@MSK | Save
  • Ivosidenib (AG-120) in mutant IDH1 relapsed/refractory acute myeloid leukemia: Results of a phase 1 study
    Meeting Abstract

    DiNardo, C. D.; Stein, E. M.; de Botton, S.; Roboz, G. J.; Altman, J. K.; Mims, A. S.; Swords, R.; Collins, R. H.; Mannis, G. N.; Pollyea, D. A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2018)

    Fulltext@MSK | Save